NASDAQ: BCTX
Briacell Therapeutics Corp Stock Forecast, Predictions & Price Target

Analyst price target for BCTX

Based on 1 analyst offering 12 month price targets for Briacell Therapeutics Corp

Min Forecast
$32.00+663.72%
Avg Forecast
$32.00+663.72%
Max Forecast
$32.00+663.72%

Should I buy or sell BCTX stock?

Based on 1 analyst offering ratings for Briacell Therapeutics Corp.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although BCTX's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates BCTX as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their BCTX stock forecasts and price targets.

BCTX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-02-03

1 of 1

Forecast return on equity

Is BCTX forecast to generate an efficient return?

Company
-79.32%
Industry
153.19%
Market
81.87%
BCTX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is BCTX forecast to generate an efficient return on assets?

Company
-27.33%
Industry
36.07%
BCTX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

BCTX earnings per share forecast

What is BCTX's earnings per share in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
-$2.45
Avg 2 year Forecast
-$1.47
Avg 3 year Forecast
-$1.09

BCTX revenue forecast

What is BCTX's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$10.1M
Avg 2 year Forecast
$35.4M
Avg 3 year Forecast
$73.0M

BCTX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
BCTX$4.19$32.00+663.72%Buy
CING$4.07$30.67+653.49%Strong Buy
UBX$0.94$4.00+325.53%Strong Buy
KAPA$0.91$8.33+813.71%Strong Buy
LPCN$3.01N/AN/A

Briacell Therapeutics Stock Forecast FAQ

Is Briacell Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: BCTX) stock is to Buy BCTX stock.

Out of 1 analyst, 0 (0%) are recommending BCTX as a Strong Buy, 1 (100%) are recommending BCTX as a Buy, 0 (0%) are recommending BCTX as a Hold, 0 (0%) are recommending BCTX as a Sell, and 0 (0%) are recommending BCTX as a Strong Sell.

If you're new to stock investing, here's how to buy Briacell Therapeutics stock.

What is BCTX's earnings growth forecast for 2025-2027?

(NASDAQ: BCTX) Briacell Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.28%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.17%.

Briacell Therapeutics's earnings in 2025 is -$11,778,491.On average, 1 Wall Street analyst forecast BCTX's earnings for 2025 to be -$9,088,128, with the lowest BCTX earnings forecast at -$9,088,128, and the highest BCTX earnings forecast at -$9,088,128. On average, 1 Wall Street analyst forecast BCTX's earnings for 2026 to be -$5,452,877, with the lowest BCTX earnings forecast at -$5,452,877, and the highest BCTX earnings forecast at -$5,452,877.

In 2027, BCTX is forecast to generate -$4,043,290 in earnings, with the lowest earnings forecast at -$4,043,290 and the highest earnings forecast at -$4,043,290.

What is BCTX's revenue growth forecast for 2027-2029?

(NASDAQ: BCTX) Briacell Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.48%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.37%.

Briacell Therapeutics's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast BCTX's revenue for 2027 to be $37,465,344, with the lowest BCTX revenue forecast at $37,465,344, and the highest BCTX revenue forecast at $37,465,344. On average, 1 Wall Street analysts forecast BCTX's revenue for 2028 to be $131,314,176, with the lowest BCTX revenue forecast at $131,314,176, and the highest BCTX revenue forecast at $131,314,176.

In 2029, BCTX is forecast to generate $270,789,120 in revenue, with the lowest revenue forecast at $270,789,120 and the highest revenue forecast at $270,789,120.

What is BCTX's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: BCTX) forecast ROA is -27.33%, which is lower than the forecast US Biotechnology industry average of 36.07%.

What is BCTX's Price Target?

According to 1 Wall Street analyst that have issued a 1 year BCTX price target, the average BCTX price target is $32.00, with the highest BCTX stock price forecast at $32.00 and the lowest BCTX stock price forecast at $32.00.

The Wall Street analyst predicted that Briacell Therapeutics's share price could reach $32.00 by Feb 3, 2026. The average Briacell Therapeutics stock price prediction forecasts a potential upside of 663.72% from the current BCTX share price of $4.19.

What is BCTX's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: BCTX) Briacell Therapeutics's current Earnings Per Share (EPS) is -$5.03. On average, analysts forecast that BCTX's EPS will be -$2.45 for 2025, with the lowest EPS forecast at -$2.45, and the highest EPS forecast at -$2.45. On average, analysts forecast that BCTX's EPS will be -$1.47 for 2026, with the lowest EPS forecast at -$1.47, and the highest EPS forecast at -$1.47. In 2027, BCTX's EPS is forecast to hit -$1.09 (min: -$1.09, max: -$1.09).

What is BCTX's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: BCTX) forecast ROE is -79.32%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.